Patient Nonadherence in Clinical Trials: Could There Be a Link to Postmarketing Patient Safety?

Drug Information Journal

Volumn 46, Issue 1, 2012, Pages 27-34

  Smith, Dorothy L ^a  

^a Consumer Health Information Corporation ^*  (United States)

Author keywords

clinical trials; informed consent; patient adherence; patient education; patient safety; study participant adherence

Indexed keywords

DRUG;

CLINICAL RESEARCH; DRUG APPROVAL; DRUG RESEARCH; DRUG SAFETY; HEALTH HAZARD; HUMAN; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SAFETY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REVIEW; TREATMENT REFUSAL;

EID: 84864796565     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/0092861511428300     Document Type: Review

References (46)

1. Matsui D.Strategies to measure and improve patient adherence in clinical trials.Pharm Med. 2009;23 (5-6): 289-297.
2. Soutter BR,Kennedy MC.Patient compliance assessment in drug trials: usage and methods.Aust N Z J Med. 1974;4:360-364.
3. Jayaraman S,Rieder MJ,Matsui DM.Compliance assessment in drug trials: has there been improvement in two decades?.Can J Clin Pharmacol. 2005;12 (3): e251-e253.
4. BosworthHBBurkholderR. Medication adherence: making the case for increased awareness. Surgeon General joins with National Consumers League to launch medication adherence awareness campaign. May11, 2011. http://scriptyourfuture.org/wp-content/themes/cons/m/Script_Your_Future_Briefing_Paper.pdf.
5. Cohen J.How celecoxib could be safer, how valdecoxib might have been.Ann Pharmacother. 2005;39:1542-1545.
6. FDA alert for healthcare professionals. Celecoxib (marketed as Celebrex). Rockville, MD: US Food and Drug Administration, Center for Drug Evaluation and Research; April7, 2005. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124655.htm. Accessed July 18, 2011.
7. Physicians' Desk Reference. 59th ed. Montvale, NJ: Medical Economics Company; 2005:3095-3099.Montvale, NJ: Medical Economics Company; 2005:3095-3099.
8. Bensen WG,Fiechtner JJ,McMillen JI, et al.Treatment of osteoarthritis with celecoxib: a randomized controlled trial.Mayo Clinic Proc. 1999;74:1095-1105.
9. US Food and Drug Administration. FDA announces new safety recommendations for high-dose simvastatin. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm258338.htm. Accessed July 1, 2011.
10. Zocor[package insert]. Whitehouse Station, NJ: Merck & Co; June2011. http://www.merck.com/product/usa/pi_circulars/z/zocor/zocor_pi.pdf. Accessed June 30, 2011.
11. Urquhart J.Role of patient compliance in clinical pharmacokinetics.Clin Pharmacokinet. 1994;27:202-215.
12. Borrelli B.The assessment, monitoring, and enhancement of treatment fidelity in public health clinical trials.J Public Health Dent. 2011;71:S52-S63.
13. Schron E,Czajkowski S.Compliance in Healthcare and Research. Burke LEOckene IS, ed. Armonk, NY: Futura; 2001:237-246.
14. Serebruany VL,Oshrine BR,Malinin AI, et al.Noncompliance in cardiovascular clinical trials.Am Heart J. 2005;150:882-886.
15. Farmer KC.Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice.Clin Ther. 1999;21:1074-1090.
16. Serebruany VL,Hanley DA,Atar D, et al.Noncompliance in antiplatelet trials: the AGATE trial perspective [letter].Stroke. 2004;35:e143.
17. Kastrissios H,Blaschke TF.Medication compliance as a feature in drug development.Annu Rev Pharmacol Toxicol. 1997;37:451-475.
18. Shumaker Sa,Dugan E,Bowen DJ.Enhancing adherence in randomized controlled clinical trials.Control Clin Trials. 2000;21 (5): 2265-2328.
19. Rand CS,Wise RA,Nides M, et al.Metered-dose inhaler adherence in a clinical trial.Am Rev Respir Dis. 1992;146:1559-1564.
20. Rand C,Bilderback A,Schiller K, et al.Adherence with montelukast or fluticasone in a long-term clinical trial: results from the mild asthma montelukast versus inhaled corticosteroid trial.J Allergy Clin Immunol. 2007;119:916-923.
21. Simmons MS,Nides MA,Rand CS, et al.Unpredictability of deception in compliance with physician-prescribed bronchodilator inhaler use in a clinical trial.Chest. 2000;118:290-295.
22. Mawhinney H,Spector SL,Kinsman RA, et al.Compliance in clinical trials of two nonbronchodilator, antiasthma medications.Ann Allergy. 1991;66:294-299.
23. Coutts JAP,Gibson NA,Paton JY.Measuring compliance with inhaled medication in asthma.Arch Dis Child. 1992;67:332-333.
24. SheltonDL. Patients in clinical trials don't always follow the program. American Medical News. September11, 2000. http://www.ama-assn.org/amednews/2000/09/11/hlsb0911.htm. Accessed July 18, 2011.
25. US Food and Drug Administration. Guidance for Industry: E6 Good Clinical Practice: Consolidated Guidance. April1996. http://www.fda.gov/cder/guidance/959fnl.pdf. Accessed July 18, 2011.
26. The Joint Commission. "What did the doctor say?" Improving health literacy to protect patient safety. 2007. http://www.jointcommission.org/assets/1/18/improving_health_literacy.pdf. Accessed July 18, 2011.
27. Hopper KD,TenHave TR,Tully DA, et al.The readability of currently used surgical/procedure consent forms in the United States.Surgery. 1998;123 (5): 496-503.
28. Cassileth BR,Zupkis RV,Sutton-Smith K, et al.Informed consent-why are its goals imperfectly realized?.N Engl J Med. 1980;302:896-900.
29. Davis TC,Holcombe RF,Berkel HJ, et al.Informed consent for clinical trials: a comparative study of standard versus simplified forms.J Natl Cancer Inst. 1998;90:668-674.
30. Grossman SA,Piantadosi S,Covahey C.Are informed consent forms that describe clinical oncology research protocols readable by most patients and their families?.J Clin Oncol. 1994;12:2211-2215.
31. Paasche-Orlow MK,Jacob DM,Hochhauser M, et al.National survey of patients' Bill of Rights statutes.J Gen Intern Med. 2009;24 (4): 489-494.
32. Meade C,Howser DM.Consent forms: how to determine and improve their readability.Oncol Nurs Forum. 1992;19:1523-1528.
33. Christopher PP,Foti ME,Roy-Bujnowski K, et al.Consent form readability and education levels of potential participants in mental health research.Psychiatr Serv. 2007;58:227-232.
34. RidpathJRGreeneSMWieseCJ. PRISM Readability Toolkit. 3rd ed. Seattle, WA: Group Health Research Institute; 2007. http://www.grouphealthresearch.org/capabilities/readability/ghchs_readability_toolkit.pdf. Accessed July 13, 2011.
35. Jefford M,Moore R.Improvement of informed consent and the quality of consent documents.Lancet Oncol. 2008;9:485-493.
36. Davis TC,Fredrickson DD,Arnold C, et al.A polio immunization pamphlet with increased appeal and simplified language does not improve comprehension to an acceptable level.Patient Educ Couns. 1998;33:25-37.
37. Cheung WY,Pond GR,Heslegrave RJ, et al.The contents and readability of informed consent forms for oncology clinical trials.Am J Clin Oncol. 2010;33 (4): 387-392.
38. Joffe S,Cook EF,Cleary PD, et al.Quality of informed consent in cancer clinical trials: a cross-sectional survey.Lancet. 2001;358:1772-1777.
39. Daugherty CK,Ratain MJ,Grochowski E, et al.Perceptions of cancer patients and their physicians involved in phase I trials.J Clin Oncol. 1995;13:1062-1072.
40. Meropol NJ,Weinfurt KP,Burnett CB, et al.Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patient communication.J Clin Oncol. 2003;21:2589-2596.
41. SullivanJ. Subject recruitment and retention: barriers to success. Applied Clinical Trials Online. April2004. http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/Patient%2FSubject+Recruitment/Subject-Recruitment-and-Retention-Barriers-to-Succ/ArticleStandard/Article/detail/89608. Accessed July 18, 2011.
42. Stone AA,Shiffman S,Schwartz JE, et al.Patient non-compliance with paper diaries.BMJ. 2002;324:1193-1194.
43. Center Watch. Smart-pill technology could monitor patient compliance while improving clinical trial data quality. http://www.centerwatch.com/news-online/headline-details.aspx?HeadlineID=1338. Accessed June 29, 2011.
44. Christensen A,Osterberg LG,Hansen EH.Electronic monitoring of patient adherence to oral antihypertensive medical treatment: a systematic review.J Hypertens. 2009;27:1540-1551.
45. Miloh T,Annunziato R,Arnon R, et al.Improved adherence and outcomes for pediatric liver transplant recipients by using text messaging.Pediatrics. 2009;124:e844-e850.
46. Lester RT,Ritvo P,Mills EJ, et al.Effects of a mobile phone short message service on antiretroviral treatment in Kenya (WelTel Kenya1): a randomised trial.Lancet. 2010;376:1838-1845.